Selective RET Inhibitors: Precision Targeting of RET Fusions and Mutations Across Tumor Types

Selpercatinib and pralsetinib deliver biomarker-driven efficacy in RET-altered NSCLC, medullary thyroid cancer, and thyroid cancer—outperforming older multikinase inhibitors with improved selectivity and CNS penetration.

bt-corporate · 6/28/2026, 1:51:41 PM · Ask about this →